$0.00
Register for Meetings
“In The News” & “Cardiovascular Marketplace” Content Access
Listen to Podcasts
Watch On-Demand Content
CardioTube Access
Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference
Access Recorded Interviews
Download PPT Slide Decks
Already have an account? Login Now
$650 Annually
Complimentary subscription to electronic version of the CRM Journal
Access to CRT Meeting Registration Discounts
CRT Premium Content, including on-demand videos and presentation downloads
Nathan Gray, CRTonline.org
A candidate oral PCSK9 inhibitor from Merck is safe and effective at lowering low-density lipoprotein (LDL)-cholesterol by 65% in adults already receiving statin therapy, Phase I trial data reveal.
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details